Literature DB >> 19166591

Perfused human organs versus Mary Shelley's Frankenstein.

Lawrence Leung1.   

Abstract

Novel drugs have to go through mandatory pre-clinical testing before they can be approved for use in clinical trials. In essence, it is a form of bench-to-bedside (N2B) translational medicine, but the wastage rate of target candidates is immensely high. Effects seen in vitro often do not translate to in vivo human settings. The search is on for better models closer to human physiology to be used in pre-clinical drug screening. The Ex Vivo Metrics system has been introduced where a human organ is harvested and revitalized in a controlled environment suitable for testing of both drug efficacy and potential toxicity. This commentary expresses the author's views regarding this technology of perfused human organs.

Entities:  

Mesh:

Year:  2009        PMID: 19166591      PMCID: PMC2633317          DOI: 10.1186/1479-5876-7-9

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  5 in total

1.  Translational science: what is it and why is it so important?

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2003-09-15       Impact factor: 7.851

2.  Can Mary Shelley's Frankenstein be read as an early research ethics text?

Authors:  H Davies
Journal:  Med Humanit       Date:  2004-06

3.  Towards gene therapy for Parkinson's disease.

Authors:  Stéphane Palfi
Journal:  Lancet Neurol       Date:  2008-04-02       Impact factor: 44.182

4.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

Review 5.  Ex Vivo Metrics, a preclinical tool in new drug development.

Authors:  C Gerald Curtis; Kevin Bilyard; Hugo Stephenson
Journal:  J Transl Med       Date:  2008-01-23       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.